Technology Review profiles next-gen sequencing company Pacific Biosciences, which has raised $178 million to develop its zero mode waveguide technology. According to the article, the company's got 12 prototype instruments churning out data. And with read lengths targeting thousands of bases, PacBio has its eye on the medical market, where "we'll be able to detect rare mutations with unprecedented accuracy," says CTO Steve Turner.